Clinical trials: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic Syndrome
ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study
The ENDOCARE-SCREEN study is a single-center, observational, cross-sectional screening study designed to assess the prevalence, phenotypes, and determinants of metabolic dysfunction-associated steatotic liver disease…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic Syndrome, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- ENDOCARE-SCREE (NCT07336563)
- Where
- Poland
- Volunteers
- 10,000 people
- Sponsor
- Jarosław Drobnik
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight
EVOO and Metabolic Liver Health in MASLD
MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and…
- Trial name
- EvoLiveR (NCT07412444)
- Testing
- Oil Supplementation - 3 tablespoons of oil, 9 Tablespoons of Oil
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Fatty Liver, Nonalcoholic
Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease
Probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
- Trial name
- NCT06491342
- Testing
- Probiotic
- Where
- 2 sites in Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug…
- Trial name
- NCT05648214
- Testing
- ALN-PNP
- Where
- 6 sites in United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
T2DM (Type 2 Diabetes Mellitus), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease
This study is designed to evaluate the efficacy, safety, and mechanisms of pulsENDO procedure in patients with T2DM and its effect on MASLD.
- Conditions
- T2DM (Type 2 Diabetes Mellitus), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Syndrome (MetS)
- Trial name
- DRESS-1 (NCT07390422)
- Testing
- pulsENDO treatment
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism
Hypothyroidism and Liver Fibrosis Severity in MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, characterized by excess fat accumulation in the liver associated with metabolic risk factors such as obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07793279
- Volunteers
- 85 people
- Sponsor
- Assiut University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic…
- Trial name
- NCT06836609
- Testing
- ALN-CIDEB
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 118 people
- Sponsor
- Regeneron Pharmaceuticals
MASLD, Fibrosis of Liver
Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI
The goal of this clinical trial is to learn whether an artificial intelligence (AI) tool called FibroX can help primary care providers better diagnose significant liver fibrosis (≥F2) and clinically significant portal…
- Trial name
- NCT07305324
- Testing
- FibroX, Usual Care
- Volunteers
- 40 people
- Sponsor
- Yale University
Metabolic Dysfunction-Associated Steatotic Liver Disease
Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Study Title: Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (D-FIB-MASLD) Objective: This study aims to assess…
- Trial name
- DEFIB-MASLD (NCT06920316)
- Testing
- Gro Health digital application
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- St. George's Hospital, London
Obesity, Liver Diseases
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting…
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat
- Trial name
- NCT06138821
- Testing
- ESG + lifestyle modification, Lifestyle modification
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Pichamol Jirapinyo, MD, MPH
Metabolic Dysfunction-associated Steatotic Liver Disease
Reducing Barriers to Lifestyle Modification for Newly Diagnosed MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of liver disease in the world. It is estimated that 38% of American children with obesity have steatotic liver disease.
- Trial name
- NCT06483711
- Testing
- Lifestyle Kit
- Volunteers
- 50 people
- Sponsor
- Stanford University
Metabolic Dysfunction-Associated Steatotic Liver Disease
Fibrosis and Metabolic Markers in Relation to PREVENT Cardiovascular Risk in MASLD
This retrospective observational study evaluates the relationship between non-invasive liver fibrosis and metabolic markers and estimated cardiovascular risk in adults with metabolic dysfunction-associated steatotic liver disease…
- Trial name
- MASLD-PREVENT (NCT07791589)
- Where
- Turkey (Türkiye)
- Volunteers
- 271 people
- Sponsor
- Özgür Bahadır
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers
Overall design: The study will include one intervention based on Mediterranean diet plus structured lifestyle intervention (150 min/week of moderate-intensity or 75 min/week of high-intensity exercise) for a total of 16 weeks.
- Trial name
- UNMASK (NCT07652151)
- Testing
- Multimodal lifestyle intervention
- Where
- 3 sites in Italy, Spain and 1 more
- Volunteers
- 450 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Liver Fibrosis, Portal Hypertension
- Trial name
- ENDO-MASH (NCT07877272)
- Testing
- Non-invasive MASLD and portal hypertension assessment, Single-session endohepatology assessment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital Muenster
Metabolic Dysfunction-Associated Steatotic Liver Disease
Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation
Metabolic dysfunction-associated steatotic liver disease (MASLD), redefined in 2020, is an improved diagnostic standard evolved from non-alcoholic fatty liver disease (NAFLD), emphasizing the correlation between hepatic steatosis…
- Trial name
- MASLD (NCT07488975)
- Testing
- Pasteurized Akkermansia muciniphila LWHK0003_low dose, Pasteurized Akkermansia muciniphila LWHK0003_medium dose, Pasteurized Akkermansia muciniphila LWHK0003_high dose
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Leeuwenhoek Laboratories Co. Ltd.
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Integrating Hepatological, Nutritional, and Psychological Support as a Multidisciplinary Management to Improve Long-term Clinical Outcomes in MASLD
Metabolic dysfunction associated Steatotic Liver Disease (MASLD) is frequently complicated by cardiometabolic (CMR) comorbidities, and prognosis is substantially influenced by acute cardiovascular events (ACE).
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, Cardiovascular Events
- Trial name
- CoCoNut (NCT07366463)
- Testing
- Hepatologic-provided recommendations, Nutritional support, Psychological support
- Where
- Italy
- Volunteers
- 286 people
- Sponsor
- University of Campania Luigi Vanvitelli
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity.
- Trial name
- AdipoDROMExpo (NCT07330830)
- Where
- 3 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH)
A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database
The primary objective of this study is to estimate the proportion of people with low/intermediate/high risk of advanced fibrosis in at risk Chinese population based on the European Association for the Study of the Liver (EASL)…
- Trial name
- IMPACT MASH (NCT06741111)
- Testing
- No treatment given
- Where
- India
- Volunteers
- 1,233,970 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic…
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
- Trial name
- NCT05067621
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Yale University